Last reviewed · How we verify

NCT03466749: RESPECT

Paclitaxel Eluting Balloon Catheter in Coronary De-novo Lesions Treatment in China

Status unknown NA Last updated 12 April 2019
What this trial tests

NA trial testing Paclitaxel Eluting Balloon Catheter in Coronary Disease in 600 participants. Status unknown.

Timeline
22 February 2018
Primary endpoint
22 February 2020
31 December 2020

Quick facts

Lead sponsorXijing Hospital
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment600
Start date22 February 2018
Primary completion22 February 2020
Estimated completion31 December 2020
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Xijing Hospital

Who can join

Adults 18 to 78, any sex, with Coronary Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this Real-world study in China is evaluating the Safety and Efficacy of Paclitaxel Eluting Balloon Catheter in Coronary de-novo lesions(target vessel diameter:2.5mm-4.0mm)Treatment. And the primary point of this study is the target lesion failure of 12 months after surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Coronary Disease

Currently open trials in the same condition.

Other Xijing Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03466749.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing